Neurobo Pharmaceuticals Inc
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has com… Read more
Neurobo Pharmaceuticals Inc (NRBO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.431x
Based on the latest financial reports, Neurobo Pharmaceuticals Inc (NRBO) has a cash flow conversion efficiency ratio of -0.431x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.59 Million) by net assets ($12.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Neurobo Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Neurobo Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Neurobo Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurobo Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marvel Biosciences Corp.
PINK:MBCOF
|
0.049x |
|
Megapolitan Developments Tbk
JK:EMDE
|
-0.004x |
|
Acrux Limited
PINK:ARUXF
|
-4.086x |
|
VIOL Co. Ltd
KQ:335890
|
0.042x |
|
Tunas Alfin Tbk
JK:TALF
|
0.034x |
|
NSX Ltd
AU:NSX
|
0.587x |
|
XOX Technology Bhd
KLSE:0017
|
-0.013x |
|
Kingsmen C.M.T.I. Public Company Limited
BK:K
|
0.102x |
Annual Cash Flow Conversion Efficiency for Neurobo Pharmaceuticals Inc (2014–2023)
The table below shows the annual cash flow conversion efficiency of Neurobo Pharmaceuticals Inc from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $16.68 Million | $-10.80 Million | -0.647x | -20.19% |
| 2022-12-31 | $21.75 Million | $-11.71 Million | -0.538x | +48.06% |
| 2021-12-31 | $14.60 Million | $-15.13 Million | -1.037x | +30.62% |
| 2020-12-31 | $7.20 Million | $-10.76 Million | -1.494x | -160.96% |
| 2019-12-31 | $12.29 Million | $-7.04 Million | -0.573x | -299.51% |
| 2018-12-31 | $-76.34 Million | $-21.91 Million | 0.287x | +104.20% |
| 2017-12-31 | $3.94 Million | $-26.90 Million | -6.826x | -1175.31% |
| 2016-12-31 | $20.63 Million | $-11.04 Million | -0.535x | -221.96% |
| 2015-12-31 | $-12.38 Million | $-5.43 Million | 0.439x | +19.50% |
| 2014-12-31 | $-531.00K | $-195.00K | 0.367x | -- |